Evoke Pharma Future Growth
Future criteria checks 5/6
Evoke Pharma is forecast to grow earnings and revenue by 124.7% and 59.5% per annum respectively while EPS is expected to grow by 115.3% per annum.
Key information
124.7%
Earnings growth rate
115.3%
EPS growth rate
| Pharmaceuticals earnings growth | 23.9% |
| Revenue growth rate | 59.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Recent updates
Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely
Jan 22
Evoke to get US patent for nasal spray Gimoti
Sep 20Evoke Pharma Q2 GAAP loss per share narrows, revenue up
Aug 10Evoke Pharma gets Canadian patent linked to Gimoti nasal spray
Jul 06Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Oct 22Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?
Jul 06Evoke Pharma announces positive findings from second GIMOTI market research study
Jun 15Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book
Jun 08Evoke Pharma issued new U.S. patent covering methods of use for Gimoti
Jun 02Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit
Mar 14Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 32 | 9 | N/A | N/A | 1 |
| 12/31/2025 | 20 | 1 | N/A | N/A | 1 |
| 12/31/2024 | 10 | -5 | N/A | N/A | 1 |
| 9/30/2024 | 9 | -6 | -5 | -5 | N/A |
| 6/30/2024 | 8 | -7 | -6 | -6 | N/A |
| 3/31/2024 | 6 | -7 | -6 | -6 | N/A |
| 12/31/2023 | 5 | -8 | -5 | -5 | N/A |
| 9/30/2023 | 4 | -8 | -6 | -6 | N/A |
| 6/30/2023 | 4 | -8 | -6 | -6 | N/A |
| 3/31/2023 | 3 | -8 | -7 | -7 | N/A |
| 12/31/2022 | 3 | -8 | -7 | -7 | N/A |
| 9/30/2022 | 2 | -8 | -6 | -6 | N/A |
| 6/30/2022 | 2 | -8 | -11 | -11 | N/A |
| 3/31/2022 | 2 | -8 | -11 | -11 | N/A |
| 12/31/2021 | 2 | -9 | -12 | -12 | N/A |
| 9/30/2021 | 1 | -9 | -12 | -12 | N/A |
| 6/30/2021 | 0 | -9 | -8 | -8 | N/A |
| 3/31/2021 | 0 | -14 | -8 | -8 | N/A |
| 12/31/2020 | 0 | -13 | -7 | -7 | N/A |
| 9/30/2020 | N/A | -12 | -6 | -6 | N/A |
| 6/30/2020 | N/A | -12 | -5 | -5 | N/A |
| 3/31/2020 | N/A | -7 | -5 | -5 | N/A |
| 12/31/2019 | N/A | -7 | -6 | -6 | N/A |
| 9/30/2019 | N/A | -7 | -6 | -6 | N/A |
| 6/30/2019 | N/A | -7 | -6 | -6 | N/A |
| 3/31/2019 | N/A | -8 | -6 | -6 | N/A |
| 12/31/2018 | N/A | -8 | -7 | -7 | N/A |
| 9/30/2018 | N/A | -6 | -8 | -8 | N/A |
| 6/30/2018 | N/A | -10 | N/A | -10 | N/A |
| 3/31/2018 | N/A | -9 | N/A | -10 | N/A |
| 12/31/2017 | N/A | -12 | N/A | -9 | N/A |
| 9/30/2017 | N/A | -13 | N/A | -7 | N/A |
| 6/30/2017 | N/A | -11 | N/A | -8 | N/A |
| 3/31/2017 | N/A | -13 | N/A | -8 | N/A |
| 12/31/2016 | N/A | -11 | N/A | -9 | N/A |
| 9/30/2016 | N/A | -12 | N/A | -10 | N/A |
| 6/30/2016 | N/A | -12 | N/A | -10 | N/A |
| 3/31/2016 | N/A | -12 | N/A | -10 | N/A |
| 12/31/2015 | N/A | -12 | N/A | -10 | N/A |
| 9/30/2015 | N/A | -12 | N/A | -11 | N/A |
| 6/30/2015 | N/A | -14 | N/A | -12 | N/A |
| 3/31/2015 | N/A | -14 | N/A | -12 | N/A |
| 12/31/2014 | N/A | -13 | N/A | -12 | N/A |
| 9/30/2014 | N/A | -12 | N/A | -11 | N/A |
| 6/30/2014 | N/A | -9 | N/A | -7 | N/A |
| 3/31/2014 | N/A | -5 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EVOK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: EVOK is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EVOK is expected to become profitable in the next 3 years.
Revenue vs Market: EVOK's revenue (59.5% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: EVOK's revenue (59.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EVOK's Return on Equity is forecast to be high in 3 years time